51 related articles for article (PubMed ID: 17051618)
21. Isolation and expression analysis of foxj1 and foxj1.2 in zebrafish embryos.
Aamar E; Dawid IB
Int J Dev Biol; 2008; 52(7):985-91. PubMed ID: 18956329
[TBL] [Abstract][Full Text] [Related]
22. Rogue proliferation versus restorative protection: where do we draw the line for Wnt and forkhead signaling?
Maiese K; Chong ZZ; Shang YC; Hou J
Expert Opin Ther Targets; 2008 Jul; 12(7):905-16. PubMed ID: 18554157
[TBL] [Abstract][Full Text] [Related]
23. OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins.
Maiese K; Chong ZZ; Shang YC
Trends Mol Med; 2008 May; 14(5):219-27. PubMed ID: 18403263
[TBL] [Abstract][Full Text] [Related]
24. "Sly as a FOXO": new paths with Forkhead signaling in the brain.
Maiese K; Chong ZZ; Shang YC
Curr Neurovasc Res; 2007 Nov; 4(4):295-302. PubMed ID: 18045156
[TBL] [Abstract][Full Text] [Related]
25. A peptide that ameliorates lupus up-regulates the diminished expression of early growth response factors 2 and 3.
Sela U; Dayan M; Hershkoviz R; Lider O; Mozes E
J Immunol; 2008 Feb; 180(3):1584-91. PubMed ID: 18209054
[TBL] [Abstract][Full Text] [Related]
26. The inhibition of autoreactive T cell functions by a peptide based on the CDR1 of an anti-DNA autoantibody is via TGF-beta-mediated suppression of LFA-1 and CD44 expression and function.
Sela U; Mauermann N; Hershkoviz R; Zinger H; Dayan M; Cahalon L; Liu JP; Mozes E; Lider O
J Immunol; 2005 Dec; 175(11):7255-63. PubMed ID: 16301630
[TBL] [Abstract][Full Text] [Related]
27. Down-regulation of stromal cell-derived factor-1alpha-induced T cell chemotaxis by a peptide based on the complementarity-determining region 1 of an anti-DNA autoantibody via up-regulation of TGF-beta secretion.
Sela U; Hershkoviz R; Cahalon L; Lider O; Mozes E
J Immunol; 2005 Jan; 174(1):302-9. PubMed ID: 15611253
[TBL] [Abstract][Full Text] [Related]
28. The tolerogenic peptide hCDR1 downregulates pathogenic cytokines and apoptosis and upregulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients.
Sthoeger ZM; Sharabi A; Dayan M; Zinger H; Asher I; Sela U; Mozes E
Hum Immunol; 2009 Mar; 70(3):139-45. PubMed ID: 19280712
[TBL] [Abstract][Full Text] [Related]
29. The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine models.
Sela U; Sharabi A; Dayan M; Hershkoviz R; Mozes E
Immunology; 2009 Sep; 128(1 Suppl):e395-405. PubMed ID: 19040426
[TBL] [Abstract][Full Text] [Related]
30. The negative regulators Foxj1 and Foxo3a are up-regulated by a peptide that inhibits systemic lupus erythematosus-associated T cell responses.
Sela U; Dayan M; Hershkoviz R; Cahalon L; Lider O; Mozes E
Eur J Immunol; 2006 Nov; 36(11):2971-80. PubMed ID: 17051618
[TBL] [Abstract][Full Text] [Related]
31. A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus.
Mozes E; Sharabi A
Autoimmun Rev; 2010 Nov; 10(1):22-6. PubMed ID: 20659591
[TBL] [Abstract][Full Text] [Related]
32. A novel synthetic peptide for the specific treatment of lupus: clinical effects and mechanism of action.
Mozes E; Sela U; Sharabi A
Isr Med Assoc J; 2008 Jan; 10(1):40-2. PubMed ID: 18300570
[No Abstract] [Full Text] [Related]
33. Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus.
Sthoeger Z; Sharabi A; Mozes E
J Autoimmun; 2014 Nov; 54():60-71. PubMed ID: 24958634
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
